Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

Merck’s (MRK) stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda. Merck is investing in M&A activity to strengthen its pipeline. However, Merck’s shares have declined in the past three months as in July, ...